Market research
068270.KO Celltrion, Inc
KO KRW Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 42T
- P/E ratio
- Not available
- Analyst target
- 268232.22
- Dividend yield
- 0.4%
- Beta
- 0.3
Profile
Company facts
- Exchange
- KO
- Currency
- KRW
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- KR7068270008
- Market cap
- 42T
- P/E ratio
- Not available
- Analyst target
- 268232.22
- Dividend yield
- 0.4%
- Beta
- 0.3
About
About Celltrion, Inc
Celltrion, Inc., a biopharmaceutical company, engages in the development, production, and sale of development, production, and sale of medicinal products. It offers biosimilars, including Remsima for rheumatoid arthritis and inflammatory bowel disease; Truxima for non-hodgkin's lymphoma and chronic lymphocytic leukemia; Herzuma for metastatic breast and gastric cancer; Remsima SC and Yuflyma for rheumatoid arthritis and inflammatory bowel disease; Vegzelma for metastatic colorectal cancer and non-small cell lung cancer; Omlyclo for Asthma and urticaria; Eydenzelt for diabetic macular edema and wet age-related macular degeneration; Steqeyma for psoriasis and inflammatory bowel disease; Stoboclo/Osenvelt for osteoporosis; Avtozma for rheumatoid arthritis and active systemic juvenile idiopathic arthritis; Zymfentra for inflammatory bowel disease; and Regkirona for COVID-19, as well as CT-G07 for HIV/AIDS and Donerion Patch for Alzheimer's dementia symptoms. The company is also developing biosimilars, which are in Phase 3 clinical trials include CT-P44 for multiple myeloma, CT-P51 for melanoma and lung cancer, CT-P53 for multiple sclerosis, and CT-P55 for psoriasis, as well as CT-G20 for hypertrophic cardiomyopathy. It distributes its products in approximately 100 countries, including the United States and Europe. The company was founded in 2002 and is headquartered in Incheon, South Korea.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the 068270.KO discussion.
5 years, 5 months ago
Celltrion, Inc is currently in a long term downtrend where the price is trading 11.1% below its 200 day moving average.
From a valuation standpoint, the stock is 161.5% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 22.4.
Celltrion, Inc's total revenue rose by 30.3% to $499B since the same quarter in the previous year.
Its net income has increased by 2.7% to $98B since the same quarter in the previous year.
Finally, its free cash flow grew by 390.3% to $155B since the same quarter in the previous year.
Based on the above factors, Celltrion, Inc gets an overall score of 3/5.